ABSTRACT Introduction Phosphodiesterase type 5 (PDE5) hydrolyses cyclic guanylate
monophosphate (cGMP) specifically to 5′ GMP. PDE5 inhibitors were a breakthrough
medication that addressed a previously unfulfilled medical need. They promoted vascular
relaxation in the corpora cavernosa and penile erection during sexual stimulation. Sildenafil,
vardenafil, and tadalafil were approved then introduced as effective treatments for male
erectile dysfunction. This impact has stimulated academic, clinical, and industrial research …

We read with interest Mostafa's article [1] reviewing the current literature on the many
potential non-erectogenic uses for oral phosphodiesterase type 5 inhibitors (PDE5). An area
of research, however, that was not discussed in any detail in their review was PDE5 effects
on psychological states.